We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The companies have decided to end their research on ziritaxestat after a review of unblinded data concluded that the drug had an unacceptable benefit-risk profile. Read More
Insights from the disappointing study will advance the company’s “understanding and application” of immunotherapy, said Dave Fredrickson, executive vice president of AZ’s oncology unit. Read More
The company said it “remains committed to making its vaccine available” in India and plans to resubmit its approval request with additional information as it becomes available. Read More
COVAX officials say 240 million doses of the AstraZeneca/Oxford University vaccine will be distributed by the Serum Institute of India during the first half of the year. Read More